Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Active not recruiting 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Thoracic 2Gastrointestinal 2Sarcoma 1Lymphoid 1Head & Neck 1CNS 1

Conditions

Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Melanoma 4Endometrial Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Neoplasm Metastasis 3Rectal Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Oropharyngeal Neoplasms 1Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1Multiple Myeloma 1Mouth Neoplasms 1Laryngeal Diseases 1Hodgkin Disease 1Hepatoblastoma 1Glioblastoma 1

Interventions

pembrolizumab 62Nivolumab 40Ipilimumab 24trametinib 13dabrafenib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10binimetinib 9Cyclophosphamide 8CTLA-4 Antigen 8Biopsy 8encorafenib 7fludarabine 6Radiosurgery 6Cisplatin 6relatlimab 5cemiplimab 5atezolizumab 5Pemetrexed 5Introns 5Interleukin-2 5tislelizumab 4lenvatinib 4fludarabine phosphate 4durvalumab 4dostarlimab 4cobimetinib 4avelumab 4Radiotherapy 4Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Melanoma × dostarlimab × Clear all
NCT06521567 2025-11-12

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

GlaxoSmithKline

Phase 1/2 Active not recruiting
83 enrolled
CNSDermatologicGastrointestinalLymphoidSarcoma

Fibrolamellar hepatocellular carcinoma, Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Melanoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Tesaro, Inc.

Phase 1 Active not recruiting
463 enrolled
DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT04139902 2025-10-15

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

University of Pittsburgh

Phase 2 Active not recruiting
48 enrolled
Dermatologic

Melanoma

NCT05060432 2024-06-21

TIG-006

iTeos Therapeutics

Phase 1/2 Active not recruiting
153 enrolled
DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡